Comera Life Sciences Holdings Inc (CMRA) Gross Profit Margin starting from the third quarter 2023 to third quarter 2022, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Comera Life Sciences Holdings Inc   (NASDAQ: CMRA)


Comera Life Sciences Holdings Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CMRA Gross Profit Margin (Sep 30 2023)
Q3 		(Jun 30 2023)
Q2 		(Mar 31 2023)
Q1 		(Dec 31 2022)
Q4 		(Sep 30 2022)
Q3
Y / Y Revenue Change -41.98 %
Seq. Revenue Change -56.73 %
Revenue In Millions $0.14
Gross Profit Margin 69.22 %
Gross Profit Margin Total Ranking # 1105
Gross Profit In Millions $0.09
Y / Y Gross Profit Change -45.76 %
Seq. Gross Profit Change -63.57 %


Commenting Third Quarter 2023 Gross Profit Margin
Comera Life Sciences Holdings Inc experienced contraction in Gross Profit by -63.57 % to $0 millions and Revenue by -56.73 %, while Gross Profit Margin fell to 69.22 %, below company*s average Gross Profit Margin.


Observing third quarter 2023 results within Major Pharmaceutical Preparations industry 90 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 642 to 1105.
Learn about Gross Margin
CMRA's Gross Profit Margin third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 91
Healthcare Sector # 196
Overall # 1087

Gross Profit Margin Statistics
High Average Low
82.21 % 71.07 % 62.83 %
(Jun 30 2023)   (Jun 30 2022)


CMRA Gross Income Trends • More of CMRA's Profitabilty Ratios • CMRA Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
CMRA's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
CMRA's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for CMRA's Competitors
Gross Profit Margin Profit Margin for Comera Life Sciences Holdings Inc 's Suppliers
Gross Profit Margin Profit Margin for CMRA's Customers

You may also want to know
CMRA's Annual Growth Rates CMRA's Profitability Ratios CMRA's Asset Turnover Ratio CMRA's Dividend Growth
CMRA's Roe CMRA's Valuation Ratios CMRA's Financial Strength Ratios CMRA's Gross Profit Growth
CMRA's Roa CMRA's Inventory Turnover Ratio CMRA's Growth Rates CMRA's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2023 MRQ Gross ProfitSep 30 2023 MRQ Revenue
Intercept Pharmaceuticals inc   99.78 %$ 88.592  Millions$ 88.789  Millions
Macrogenics Inc   99.18 %$ 10.312  Millions$ 10.397  Millions
Corcept Therapeutics Inc  98.67 %$ 121.956  Millions$ 123.601  Millions
Ionis Pharmaceuticals Inc   98.48 %$ 142.016  Millions$ 144.207  Millions
Avadel Pharmaceuticals Plc  98.33 %$ 6.897  Millions$ 7.014  Millions
Tg Therapeutics Inc   97.88 %$ 162.306  Millions$ 165.815  Millions
Karyopharm Therapeutics Inc   97.47 %$ 35.098  Millions$ 36.009  Millions
Deciphera Pharmaceuticals Inc   97.03 %$ 42.027  Millions$ 43.313  Millions
Arcutis Biotherapeutics Inc   96.90 %$ 36.927  Millions$ 38.109  Millions
Travere Therapeutics Inc   96.53 %$ 35.806  Millions$ 37.095  Millions
Gyre Therapeutics Inc   96.30 %$ 30.858  Millions$ 32.042  Millions
Emmaus Life Sciences Inc   95.74 %$ 4.804  Millions$ 5.018  Millions
Lexicon Pharmaceuticals Inc   95.68 %$ 0.155  Millions$ 0.162  Millions
Rigel Pharmaceuticals Inc  95.49 %$ 26.866  Millions$ 28.134  Millions
2seventy Bio Inc   95.42 %$ 11.483  Millions$ 12.034  Millions
Blueprint Medicines Corporation  95.08 %$ 53.784  Millions$ 56.566  Millions
Zevra Therapeutics Inc   95.03 %$ 2.751  Millions$ 2.895  Millions
Amylyx Pharmaceuticals Inc   94.92 %$ 97.475  Millions$ 102.693  Millions
Marinus Pharmaceuticals Inc   93.80 %$ 6.883  Millions$ 7.338  Millions
Regeneron Pharmaceuticals Inc   93.32 %$ 3,138.200  Millions$ 3,362.700  Millions
Acadia Pharmaceuticals Inc   93.09 %$ 197.077  Millions$ 211.699  Millions
Polomar Health Services, Inc.  92.56 %$ 0.020  Millions$ 0.022  Millions
Vanda Pharmaceuticals Inc   92.11 %$ 35.752  Millions$ 38.815  Millions
Bullfrog Ai Holdings Inc   92.00 %$ 0.060  Millions$ 0.065  Millions
Silo Pharma Inc  91.91 %$ 0.017  Millions$ 0.018  Millions
Agios Pharmaceuticals Inc   91.44 %$ 6.766  Millions$ 7.399  Millions
Amicus Therapeutics inc   91.22 %$ 93.555  Millions$ 102.555  Millions
Alimera Sciences Inc  91.15 %$ 20.606  Millions$ 22.606  Millions
Ocular Therapeutix Inc   90.87 %$ 13.704  Millions$ 15.081  Millions
Aclaris Therapeutics Inc   90.86 %$ 8.434  Millions$ 9.282  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.